Content owner: Packaging Factory Direct. Published and reviewed: . This page concerns printed secondary packaging, not clinical use, product registration or medical advice.
Separate the product, primary package and secondary carton
A dermal filler packaging project may contain a pre-filled syringe, vial, needle, leaflet, tray, tamper-evident feature and printed carton. These components do not have the same function. The component in direct contact with the filled product follows a different technical and regulatory path from the printed outer carton.
The RFQ should therefore identify exactly what the packaging supplier is being asked to manufacture. A secondary-carton supplier can engineer board structure, print, inserts, code panels and converting tolerances. It cannot determine product classification, approve a sterile barrier, validate shelf life or authorize medical claims.
Dermal filler carton decision table
| Decision area | Buyer input | Supplier output to approve | Main risk if omitted |
|---|---|---|---|
| Packed-product fit | Maximum component dimensions, weight, count and orientation | Dieline, internal dimensions and insert drawing | Movement, crushing or impossible packing |
| Label content | Controlled, market-approved artwork and language versions | Prepress proof with revision identifier | Obsolete or unapproved copy |
| Variable data | Approved barcode type, data fields, human-readable text and verification rule | Reserved code area and production verification record | Unscannable or incorrectly encoded symbols |
| Tamper evidence | Required opening evidence and destination-market basis | Structural sample and closure detail | A feature that looks secure but is not validated for the intended requirement |
| Surface finish | Approved color target, varnish, foil or texture layers | Color proof and finish sample | Reduced readability, code interference or brand mismatch |
| Inspection | Defect classes, sampling plan and acceptance criteria | Inspection report tied to the production lot | Disagreement after production |
Define the artwork and coding control before quotation
The U.S. Food and Drug Administration maintains resources for prescription-drug carton and container labeling and a May 2022 guidance focused on reducing medication errors through label and carton design. These sources are relevant references for responsible artwork review; they are not a statement that a particular carton or supplier is FDA approved.
Where a buyer uses GS1 standards, GS1 identifies GS1 DataMatrix as the two-dimensional carrier used for healthcare product identification and traceability. The actual encoded elements can include identifiers such as GTIN, batch or lot, expiration date and serial number when relevant. The buyer must define which elements apply, who creates the data, how it is transferred and what verification result is acceptable.
- Assign a controlled artwork file name and revision.
- Lock the dieline before regulatory copy is flowed into the panels.
- Reserve the code area, quiet area and human-readable information defined by the approved specification.
- Separate static print from variable-data fields.
- Define whether verification covers data correctness, print quality, database reconciliation or more than one of these controls.
- Require a signed approval before plates, dies or mass production are released.
Build an evidence-based RFQ package
A quotation can only be compared fairly when suppliers receive the same specification. Send the following information as one controlled RFQ pack:
- Product configuration: component list, maximum dimensions, packed weight, units per carton and orientation.
- Structure: folding-carton style, board direction, insert or tray, closure and tamper-evidence concept.
- Artwork: editable source, approved PDF, language variants, revision history and ownership of final approval.
- Codes: symbology, data fields, source of variable data, readable text, placement and verification rule.
- Quantity: required production quantity, planned variants and acceptable overrun or underrun rules.
- Quality: critical, major and minor defect definitions plus the agreed inspection method.
- Documents: only project-specific records required by the buyer or destination market; do not request generic certificate logos without checking their applicability.
Sampling and production approval sequence
Start with a structural white sample when fit and packing order are uncertain. Move to a printed sample after the dieline is stable. Approval should cover both the empty carton and the fully packed configuration. A beautiful empty box can still fail if the syringe, leaflet or tray shifts during packing and distribution.
For a serialized design, use buyer-controlled test data during proofing and keep live production data out of uncontrolled artwork files. Record what was inspected, by whom, against which revision and with what result. If a requirement depends on the destination market, use the buyer's regulatory specification rather than a generic web checklist.
Related pages for a complete buying decision
- Custom pharmaceutical packaging boxes
- Pharmaceutical and medical packaging solutions
- Hyaluronic acid dermal filler packaging boxes
- Tamper-evident injection carton with DataMatrix panel
- Pharma packaging serialization guide
Primary sources and limitations
- FDA: Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors
- FDA: Carton and Container Labeling Resources
- GS1: 2D barcode in healthcare
These sources explain regulatory and standards context. They do not certify Packaging Factory Direct or establish that a structure is suitable for a particular filled product. Suitability, label approval, testing and market compliance remain project-specific buyer responsibilities.
FAQ for dermal filler packaging buyers
Is a printed carton the primary package for a dermal filler?
Usually no. This guide covers the printed secondary carton and its insert or tray. The syringe, vial, blister, pouch or other component that directly contains or protects the filled product must be specified and approved through the applicable product and regulatory process.
What dimensions should be sent for a dermal filler carton quote?
Send the maximum dimensions and weight of every packed component, the number of units per carton, the intended orientation, required clearance, leaflet dimensions and any tamper-evident or coding feature. A physical sample or controlled drawing is preferable to a photo alone.
Can a packaging supplier approve medical claims or regulatory label copy?
No. The brand owner, application holder or qualified regulatory team must approve medical claims, symbols, warnings, language and market-specific label copy. The packaging supplier can reproduce approved artwork and report print or code-verification results defined in the purchase specification.
Should every dermal filler box use GS1 DataMatrix?
Not automatically. Barcode type, encoded data and placement depend on product classification, market rules and the buyer's traceability system. Where GS1 standards apply, the buyer should provide the approved data structure and verification requirement before artwork approval.
What evidence should be approved before mass production?
Approve the dieline, controlled artwork revision, color target, physical sample, packed-product fit, code location and scan criteria, tamper-evidence design, defect definitions, inspection plan and the project-specific documents required for the destination market.
Request a secondary-carton quotation
Send the packed-component drawing or sample, carton quantity, approved artwork status, coding requirement, insert, finish, destination country and required inspection evidence.
Send RFQ Details